-
1
-
-
85046588922
-
Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice
-
Lanas A, Garcia-Rodriguez LA, Polo-Tomas M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009;104:1633-41.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 1633-1641
-
-
Lanas, A.1
Garcia-Rodriguez, L.A.2
Polo-Tomas, M.3
-
2
-
-
79956107773
-
Impact of upper and lower gastrointestinal blood loss on healthcare utilization and costs: A systematic review
-
Parker DR, Luo X, Jalbert JJ, et al. Impact of upper and lower gastrointestinal blood loss on healthcare utilization and costs: a systematic review. J Media Econ. 2011;14:279-87.
-
(2011)
J Media Econ
, vol.14
, pp. 279-287
-
-
Parker, D.R.1
Luo, X.2
Jalbert, J.J.3
-
3
-
-
33749681586
-
Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: Population based case-control study
-
Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333:726.
-
(2006)
BMJ
, vol.333
, pp. 726
-
-
Hallas, J.1
Dall, M.2
Andries, A.3
-
4
-
-
84885704995
-
Chapter 3: Gastrointestinal bleeding: Antiplatelets and anticoagulants
-
Sung JJ, Kuipers EJ, Barkun AN, eds. 2 ed. London: Wiley-Blackwell
-
Sung JJ. Chapter 3: Gastrointestinal bleeding: Antiplatelets and anticoagulants. In: Sung JJ, Kuipers EJ, Barkun AN, eds. Gastrointestinal bleeding. 2 ed. London: Wiley-Blackwell; 2012.
-
(2012)
Gastrointestinal Bleeding
-
-
Sung, J.J.1
-
5
-
-
80052026195
-
Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis
-
Lanas A, Wu P, Medin J, et al. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol. 2011;9:762-8.e6.
-
(2011)
Clin Gastroenterol Hepatol
, vol.9
-
-
Lanas, A.1
Wu, P.2
Medin, J.3
-
6
-
-
84876272891
-
Low-dose acetylsalicylic acid use and the risk of upper gastrointestinal bleeding: A meta-analysis of randomized clinical trials and observational studies
-
Valkhoff VE, Sturkenboom M, Hill C, et al. Low-dose acetylsalicylic acid use and the risk of upper gastrointestinal bleeding: A meta-analysis of randomized clinical trials and observational studies. Can J Gastroenterol. 2013;27:159-67.
-
(2013)
Can J Gastroenterol
, vol.27
, pp. 159-167
-
-
Valkhoff, V.E.1
Sturkenboom, M.2
Hill, C.3
-
7
-
-
84861137106
-
Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: A systematic review and meta-analysis
-
Neumann I, Rada G, Claro JC, et al. Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med. 2012;156:710-9.
-
(2012)
Ann Intern Med
, vol.156
, pp. 710-719
-
-
Neumann, I.1
Rada, G.2
Claro, J.C.3
-
8
-
-
84863981277
-
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation
-
Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110:453-60.
-
(2012)
Am J Cardiol
, vol.110
, pp. 453-460
-
-
Miller, C.S.1
Grandi, S.M.2
Shimony, A.3
-
9
-
-
80052592404
-
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
-
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91.
-
(2011)
N Engl J Med
, vol.365
, pp. 883-891
-
-
Patel, M.R.1
Mahaffey, K.W.2
Garg, J.3
-
10
-
-
70349306707
-
Dabigatran versus warfarin in patients with atrial fibrillation
-
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.
-
(2009)
N Engl J Med
, vol.361
, pp. 1139-1151
-
-
Connolly, S.J.1
Ezekowitz, M.D.2
Yusuf, S.3
-
11
-
-
84879151748
-
On the treatment of new oral anticoagulant-associated gastrointestinal hemorrhage
-
Holster IL, Hunfeld NG, Kuipers EJ, et al. On the treatment of new oral anticoagulant-associated gastrointestinal hemorrhage. J Gastrointestin Liver Dis. 2013;22:229-31.
-
(2013)
J Gastrointestin Liver Dis
, vol.22
, pp. 229-231
-
-
Holster, I.L.1
Hunfeld, N.G.2
Kuipers, E.J.3
-
12
-
-
80052413972
-
Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents
-
Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost. 2011;9:1705-12.
-
(2011)
J Thromb Haemost
, vol.9
, pp. 1705-1712
-
-
Levi, M.1
Eerenberg, E.2
Kamphuisen, P.W.3
-
13
-
-
84878051291
-
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis
-
Holster IL, Valkhoff VE, Kuipers EJ, et al. New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis. Gastroenterology. 2013;145:105-12 e15.
-
(2013)
Gastroenterology
, vol.145
-
-
Holster, I.L.1
Valkhoff, V.E.2
Kuipers, E.J.3
-
15
-
-
79960647787
-
Recent progress in anticoagulant therapy: Oral direct inhibitors of thrombin and factor Xa
-
Bauer KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost. 2011;9(Suppl 1):12-9.
-
(2011)
J Thromb Haemost
, vol.9
, Issue.SUPPL. 1
, pp. 12-19
-
-
Bauer, K.A.1
-
17
-
-
79951853381
-
The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism
-
Mavrakanas T, Bounameaux H. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacol Ther. 2011;130:46-58.
-
(2011)
Pharmacol Ther
, vol.130
, pp. 46-58
-
-
Mavrakanas, T.1
Bounameaux, H.2
-
18
-
-
79959328410
-
Practical aspects of the oral new anticoagulants
-
DeLoughery TG. Practical aspects of the oral new anticoagulants. Am J Hematol. 2011;86:586-90.
-
(2011)
Am J Hematol
, vol.86
, pp. 586-590
-
-
DeLoughery, T.G.1
-
20
-
-
35348879239
-
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)
-
Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100:1419-26.
-
(2007)
Am J Cardiol
, vol.100
, pp. 1419-1426
-
-
Ezekowitz, M.D.1
Reilly, P.A.2
Nehmiz, G.3
-
21
-
-
77954361232
-
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
-
Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633-41.
-
(2010)
Thromb Haemost
, vol.104
, pp. 633-641
-
-
Weitz, J.I.1
Connolly, S.J.2
Patel, I.3
-
22
-
-
79952513881
-
Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation
-
Chung N, Jeon HK, Lien LM, et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost. 2011;105:535-44.
-
(2011)
Thromb Haemost
, vol.105
, pp. 535-544
-
-
Chung, N.1
Jeon, H.K.2
Lien, L.M.3
-
23
-
-
79960800225
-
Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. -The ARISTOTLE-J study
-
Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. -The ARISTOTLE-J study. Circ J. 2011;75:1852-9.
-
(2011)
Circ J
, vol.75
, pp. 1852-1859
-
-
Ogawa, S.1
Shinohara, Y.2
Kanmuri, K.3
-
24
-
-
79952301326
-
Apixaban in patients with atrial fibrillation
-
Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-17.
-
(2011)
N Engl J Med
, vol.364
, pp. 806-817
-
-
Connolly, S.J.1
Eikelboom, J.2
Joyner, C.3
-
25
-
-
80052825103
-
Apixaban versus warfarin in patients with atrial fibrillation
-
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92.
-
(2011)
N Engl J Med
, vol.365
, pp. 981-992
-
-
Granger, C.B.1
Alexander, J.H.2
McMurray, J.J.3
-
26
-
-
17644409026
-
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial
-
Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3:103-11.
-
(2005)
J Thromb Haemost
, vol.3
, pp. 103-111
-
-
Eriksson, B.I.1
Dahl, O.E.2
Buller, H.R.3
-
27
-
-
28444474155
-
BAY 59-7939: An oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
-
Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005;3:2479-86.
-
(2005)
J Thromb Haemost
, vol.3
, pp. 2479-2486
-
-
Turpie, A.G.1
Fisher, W.D.2
Bauer, K.A.3
-
28
-
-
33644867218
-
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement
-
Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006;4:121-8.
-
(2006)
J Thromb Haemost
, vol.4
, pp. 121-128
-
-
Eriksson, B.I.1
Borris, L.2
Dahl, O.E.3
-
29
-
-
33751559902
-
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement
-
Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114:2374-81.
-
(2006)
Circulation
, vol.114
, pp. 2374-2381
-
-
Eriksson, B.I.1
Borris, L.C.2
Dahl, O.E.3
-
30
-
-
34250651947
-
Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement
-
Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res. 2007;120:685-93.
-
(2007)
Thromb Res
, vol.120
, pp. 685-693
-
-
Eriksson, B.I.1
Borris, L.C.2
Dahl, O.E.3
-
31
-
-
35449007749
-
Oral dabigatran etexilate vs. Subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial
-
Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178-85.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 2178-2185
-
-
Eriksson, B.I.1
Dahl, O.E.2
Rosencher, N.3
-
32
-
-
34548575058
-
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial
-
Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949-56.
-
(2007)
Lancet
, vol.370
, pp. 949-956
-
-
Eriksson, B.I.1
Dahl, O.E.2
Rosencher, N.3
-
33
-
-
36348978071
-
The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement
-
Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007;5:2368-75.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 2368-2375
-
-
Lassen, M.R.1
Davidson, B.L.2
Gallus, A.3
-
34
-
-
45949099359
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
-
Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-75.
-
(2008)
N Engl J Med
, vol.358
, pp. 2765-2775
-
-
Eriksson, B.I.1
Borris, L.C.2
Friedman, R.J.3
-
35
-
-
45949103416
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
-
Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-86.
-
(2008)
N Engl J Med
, vol.358
, pp. 2776-2786
-
-
Lassen, M.R.1
Ageno, W.2
Borris, L.C.3
-
36
-
-
46049106502
-
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial
-
Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31-9.
-
(2008)
Lancet
, vol.372
, pp. 31-39
-
-
Kakkar, A.K.1
Brenner, B.2
Dahl, O.E.3
-
37
-
-
57649123692
-
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
-
Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1-9.
-
(2009)
J Arthroplasty
, vol.24
, pp. 1-9
-
-
Ginsberg, J.S.1
Davidson, B.L.2
Comp, P.C.3
-
38
-
-
60849097858
-
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)
-
Turpie AG, Bauer KA, Davidson BL, et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost. 2009;101:68-76.
-
(2009)
Thromb Haemost
, vol.101
, pp. 68-76
-
-
Turpie, A.G.1
Bauer, K.A.2
Davidson, B.L.3
-
39
-
-
65549169515
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial
-
Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373:1673-80.
-
(2009)
Lancet
, vol.373
, pp. 1673-1680
-
-
Turpie, A.G.1
Lassen, M.R.2
Davidson, B.L.3
-
40
-
-
68249158084
-
Apixaban or enoxaparin for thromboprophylaxis after knee replacement
-
Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361:594-604.
-
(2009)
N Engl J Med
, vol.361
, pp. 594-604
-
-
Lassen, M.R.1
Raskob, G.E.2
Gallus, A.3
-
41
-
-
78249262614
-
Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with a safety profile comparable to placebo
-
Fuji T, Fuijita S, Ujihira T, et al. Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with a safety profile comparable to placebo. J Arthroplasty. 2010;25:1267-74.
-
(2010)
J Arthroplasty
, vol.25
, pp. 1267-1274
-
-
Fuji, T.1
Fuijita, S.2
Ujihira, T.3
-
42
-
-
78149236861
-
A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty
-
Fuji T, Fujita S, Tachibana S, et al. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost. 2010;8:2458-68.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 2458-2468
-
-
Fuji, T.1
Fujita, S.2
Tachibana, S.3
-
43
-
-
78650587760
-
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement
-
Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363:2487-98.
-
(2010)
N Engl J Med
, vol.363
, pp. 2487-2498
-
-
Lassen, M.R.1
Gallus, A.2
Raskob, G.E.3
-
44
-
-
77649113258
-
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial
-
Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375:807-15.
-
(2010)
Lancet
, vol.375
, pp. 807-815
-
-
Lassen, M.R.1
Raskob, G.E.2
Gallus, A.3
-
45
-
-
77956628530
-
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study
-
Raskob G, Cohen AT, Eriksson BI, et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010;104:642-9.
-
(2010)
Thromb Haemost
, vol.104
, pp. 642-649
-
-
Raskob, G.1
Cohen, A.T.2
Eriksson, B.I.3
-
46
-
-
79953836474
-
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial
-
Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011;105:721-9.
-
(2011)
Thromb Haemost
, vol.105
, pp. 721-729
-
-
Eriksson, B.I.1
Dahl, O.E.2
Huo, M.H.3
-
47
-
-
83155193223
-
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients
-
Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167-77.
-
(2011)
N Engl J Med
, vol.365
, pp. 2167-2177
-
-
Goldhaber, S.Z.1
Leizorovicz, A.2
Kakkar, A.K.3
-
48
-
-
84860495892
-
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
-
Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012;10:807-14.
-
(2012)
J Thromb Haemost
, vol.10
, pp. 807-814
-
-
Levine, M.N.1
Gu, C.2
Liebman, H.A.3
-
49
-
-
34447317298
-
Treatment of proximal deepvein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study
-
Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deepvein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007;116:180-7.
-
(2007)
Circulation
, vol.116
, pp. 180-187
-
-
Agnelli, G.1
Gallus, A.2
Goldhaber, S.Z.3
-
50
-
-
53849123533
-
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: The Einstein-DVT Dose-Ranging Study
-
Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008;112:2242-7.
-
(2008)
Blood
, vol.112
, pp. 2242-2247
-
-
Buller, H.R.1
Lensing, A.W.2
Prins, M.H.3
-
51
-
-
47649098524
-
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
-
Buller H, Deitchman D, Prins M, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008;6:1313-8.
-
(2008)
J Thromb Haemost
, vol.6
, pp. 1313-1318
-
-
Buller, H.1
Deitchman, D.2
Prins, M.3
-
52
-
-
71849117615
-
Dabigatran versus warfarin in the treatment of acute venous thromboembolism
-
Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-52.
-
(2009)
N Engl J Med
, vol.361
, pp. 2342-2352
-
-
Schulman, S.1
Kearon, C.2
Kakkar, A.K.3
-
53
-
-
78650619315
-
Oral rivaroxaban for symptomatic venous thromboembolism
-
Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499-510.
-
(2010)
N Engl J Med
, vol.363
, pp. 2499-2510
-
-
Bauersachs, R.1
Berkowitz, S.D.2
Brenner, B.3
-
54
-
-
84859385808
-
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
-
Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287-97.
-
(2012)
N Engl J Med
, vol.366
, pp. 1287-1297
-
-
Buller, H.R.1
Prins, M.H.2
Lensin, A.W.3
-
55
-
-
67649563209
-
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial
-
Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877-85.
-
(2009)
Circulation
, vol.119
, pp. 2877-2885
-
-
Alexander, J.H.1
Becker, R.C.2
Bhatt, D.L.3
-
56
-
-
67649562905
-
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial
-
Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374:29-38.
-
(2009)
Lancet
, vol.374
, pp. 29-38
-
-
Mega, J.L.1
Braunwald, E.2
Mohanavelu, S.3
-
57
-
-
80052162121
-
Apixaban with antiplatelet therapy after acute coronary syndrome
-
Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699-708.
-
(2011)
N Engl J Med
, vol.365
, pp. 699-708
-
-
Alexander, J.H.1
Lopes, R.D.2
James, S.3
-
58
-
-
84862907587
-
Rivaroxaban in patients with a recent acute coronary syndrome
-
Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19.
-
(2012)
N Engl J Med
, vol.366
, pp. 9-19
-
-
Mega, J.L.1
Braunwald, E.2
Wiviott, S.D.3
-
59
-
-
80052232522
-
Dabigatran vs. Placebo in patients with acute coronary syndromes on dual antiplatelet therapy: A randomized, double-blind, phase II trial
-
Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32:2781-9.
-
(2011)
Eur Heart J
, vol.32
, pp. 2781-2789
-
-
Oldgren, J.1
Budaj, A.2
Granger, C.B.3
-
60
-
-
84863224773
-
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: Systematic review, meta-analysis, and indirect treatment comparisons
-
Gómez-Outes A, Terleira-Fernandez AI, Suarez-Gea ML, et al. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ. 2012;344:e3675.
-
(2012)
BMJ
, vol.344
-
-
Gómez-Outes, A.1
Terleira-Fernandez, A.I.2
Suarez-Gea, M.L.3
-
61
-
-
33847328353
-
Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants
-
Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007;102:507-15.
-
(2007)
Am J Gastroenterol
, vol.102
, pp. 507-515
-
-
Lanas, A.1
Garcia-Rodriguez, L.A.2
Arroyo, M.T.3
|